The trial tech firm says analysis of trials in low- and middle-income regions reveals that innovative statistical methods could make a huge difference.
This month’s news on new hires, board launches, acquisitions, and other important news includes items on Pfizer, Javara, Clinical Ink, and other companies.
According to patient-matching specialist TrialJectory, 90% of cancer patients know the vitality of genetic testing but more than half are not being tested.
The #BlackDataMatters movement aims to improve outcomes for Black women living with breast cancer by increasing their presence in vital clinical research.
Cota has released a survey revealing about two-thirds of cancer patients and their families are unsatisfied at the speed of cancer treatment development.
A leader from the rare and infectious disease treatment specialist talks about ongoing research into a potential treatment for mild-to-moderate COVID-19.
Merck (known as MSD outside the US and Canada) will partner with the data insights firm on solutions that progress real-world research and innovations.
A study conducted by trial tech firms Curedatis and Climedo Health reveals what trial professionals view as challenges and opportunities in digitalization.
The International Vaccine Institute (IVI) and Bharat Biotech have started a Phase 2/3 clinical trial for a chikungunya vaccine candidate in Costa Rica.
The CRO has launched an initiative that offers help navigating regulatory issues for ultra-rare disease patient advocacy groups that demonstrate a need.
The two firms will work together on solutions to connect de-identified, first-party data to real-world data to help advance precision medicine development.
The digital pathology firm and image-analysis software developer will partner on artificial intelligence based solutions to improve trial decision making.
The patient matching platform firm will work with Precision for Medicine on solutions to increase diversity, elevate enrollment and speed new therapies.
The pjarmaceutical excipient, intended for use in the formulation of flash orally dissolving tablets, is designed to disintegrate in less than 10 seconds.
A leader from the excipients firm discusses how ODTs appeal to seniors and patients on the go, and the formulation-related challenges with such tablets.
A representative from Clarivate explains how supply chain vulnerabilities can hurt stakeholders, including patients—and how one solution can close the gap.
An executive from the digital therapeutics specialist discusses the clinical trial landscape, and how clinical care can yield a number of important benefits.
A leader from Veeva Systems shares perspective on what factors are impacting clinical trial data management, and how the industry can adapt to the changes.
This month’s roundup of equipment, decentralized technology, partnerships and other items includes news from Medidata, PerkinElmer, Syneos and other firms.
The National Institute on Aging has launched Outreach Pro, an online tool aimed to help connect with underrepresented populations for Alzheimer’s trials.
The check-in with nearly 1,800 US healthcare consumers reflects how COVID-19 and other factors have impacted patient access, equity, experience and trust.
The World Health Organization’s Solidarity PLUS trial will kick off in 52 countries, trialing three drugs to treat patients hospitalized with COVID-19.
The Heart of Athletes study, using Deloitte’s ConvergeHealth MyPath for Clinical platform, aims to examine heart inflammation in athletes with the virus.
The clinical study network is partnering with the Wisconsin-based health system to increase the reach of trials into a largely rural patient population.
The pharma firm is working with five US colleges and universities onto create programming designed to boost recruitment of Black talent in the industry
A leader from Longboat by Advarra outlines what it really means for a study to be patient centric, and how to succeed in achieving patient-centric trials.
Producers of CPhI North America 2021 offer a glimpse at programming, including sessions on COVID-19 challenges, supply chain issues, and more key topics.
The Psychae Institute, established by a global team of scientists, will conduct pre-clinical and clinical research around psychedelic medicine development.
The two companies are collaborating to research, develop and launch new small-molecule drug candidates aimed at treating obesity and related comorbidities.
A leader from the topical solutions centered CDMO discusses the differences between approaches by the FDA and EMA, and how to deal with them effectively.
The BiovitalsHF, from Biofourmis, is intended to augment decision-making in clinical environments, and to supplement traditional pharmaceutical therapies.
A new UK eLearning program is targeted at healthcare and academic professionals to support their learning on advanced therapy medicinal products (ATMPs).
The health data specialist and pharma firm are partnering on solutions around remote collection of digital data for detection and monitoring of treatments.
A leader from the artificial intelligence solutions firm discusses how advanced analytical tools can help researchers make the most of mountains of data.
A recent survey conducted by dosing technology firm found that the vast majority (85%) of patients think that personalized medicine stands to improve care.
A recent study indicates patients taking the cholesterol-lowering drugs prior to COVID hospitalization are far less likely to die as a result of the virus.
The oncology-centered analytics firm will work with the DC-area healthcare provider to delve into discovery and development of novel cancer treatments.
A representative from the medication management solutions company suggests patient behavior data can be used to improve adherence to trial drug regimens.
The two companies will work together to come up with solutions that use machine learning and artificial intelligence to help accelerate innovation in R&D.
According to a leader from CRO Quanticate, the research industry’s increased use of real-world data is leading to a broad range of benefits in trial work.
The agency’s effort to fight the deadly disease now includes taps the pharma company’s testing tools to help speed up diagnosis and grow treatment access.
During the Rare/Orphan Diseases, Special Patient Population webinar, a group of industry experts discussed challenges and opportunities faced in the field.
The immunotherapy firm is conducting a Phase III trial centered on an innovative approach to treating recurrent glioblastoma, an aggressive brain cancer.
